Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Event Monitoring and Evaluation by Community Pharmacists in Japan: A Pilot Study on Fenofibrate and Pemafibrate

Author(s): Masao Takahashi, Nobuhiro Ooba*, Marina Nagamura, Makoto Ushida, Eiji Kawakami, Masaomi Kimura, Tsugumichi Sato, Yoshinori Takahashi, Junichi Tokuyoshi, Hajime Hashiba, Miwako Kamei, Choichiro Miyazaki and Mitsuaki Shimada

Volume 17, Issue 4, 2022

Published on: 11 April, 2022

Page: [350 - 356] Pages: 7

DOI: 10.2174/1574886317666220224142511

open access plus

Abstract

Background: The Japan Pharmaceutical Association has conducted drug event monitoring to detect drug events related to pemafibrate. As there are a few studies on the safety of pemafibrate in clinical settings, a pilot study evaluating the association between drug use and detected events was performed in Japan.

Aims: In this study, the association between detected events and the use of pemafibrate, utilizing pharmacy records maintained by community pharmacists, was investigated. We identified the newuser cohort using a test and active comparison drug and collected the baseline information. An active comparison group comprising new users was used to assess the events.

Methods: A retrospective cohort study using questionnaires regarding baseline and event data was conducted by community pharmacists belonging to the Japan Pharmaceutical Association. The incidence of event and estimated hazard ratio were calculated using the Cox proportional hazards model that was adjusted for confounding factors, such as age and sex.

Results: A total of 1294 patients using pemafibrate and 508 patients using fenofibrate were identified as new drug users. The most reported events involving suspected adverse reactions and add-on drugs were increased blood pressure and lipid-lowering effects with pemafibrate use, and nasopharyngitis, pruritus, dizziness, and lipid-lowering effects with fenofibrate use. No significant differences were found in commonly occurring events, except that an add-on anti-hypertensive drug has been used by pemafibrate users compared to fenofibrate users.

Conclusion: This study conducted by pharmacists can facilitate the safety assessment of newly marketed drugs, as few drug use investigations with a comparator are carried out by the Japanese authority for pharmaceutical companies. However, further research is required.

Keywords: Retrospective cohort study, new-user design, event monitoring, concurrent control, primary data collection, community pharmacist.

« Previous Next »
Graphical Abstract

[1]
Rawson NS, Pearce GL, Inman WH. Prescription-event monitoring: methodology and recent progress. J Clin Epidemiol 1990; 43(5): 509-22.
[http://dx.doi.org/10.1016/0895-4356(90)90140-K] [PMID: 2324790]
[2]
Layton D, Hazell L, Shakir SA. Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk management. Drug Saf 2011; 34(12): e1-9.
[http://dx.doi.org/10.2165/11593830-000000000-00000]
[3]
Osborne V, Shakir SA. Event monitoring in the UK. In: Strom BL, Kimmel SE, Hennessy S, Eds. Pharmacoepidemiology. 6th ed. New Jersey: Wiley-Blackwell 2020; pp. 307-41.
[4]
Clark DW, Harrison-Woolrych M. The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions. Curr Drug Saf 2006; 1(2): 169-78.
[http://dx.doi.org/10.2174/157488606776930544] [PMID: 18690928]
[5]
Kubota K. A design for prescription-event monitoring in Japan (J-PEM). Pharmacoepidemiol Drug Saf 1999; 8(6): 447-56.
[http://dx.doi.org/10.1002/(SICI)1099-1557(199910/11)8:6<447:AID-PDS446>3.0.CO;2-I] [PMID: 15073906]
[6]
Tanaka K, Morita Y, Kawabe E, Kubota K. Drug use investigation (DUI) and prescription-event monitoring in Japan (J-PEM). Pharmacoepidemiol Drug Saf 2001; 10(7): 653-8.
[http://dx.doi.org/10.1002/pds.642] [PMID: 11980256]
[7]
The Japan Pharmaceutical Association. Available from: https://www.nichiyaku.or.jp/assets/uploads/about/anuual_report2020j.pdf [cited: 9th July 2021].
[8]
Hayashi S, Nanaumi A, Akiba Y, Komiyama T, Takeuchi K. Collection of medical drug information in pharmacies: Drug Event Monitoring (DEM) in Japan. Yakugaku Zasshi 2005; 125(7): 555-65.
[http://dx.doi.org/10.1248/yakushi.125.555] [PMID: 15997212]
[9]
Mann RD. Prescription-event monitoring-recent progress and future horizons. Br J Clin Pharmacol 1998; 46(3): 195-201.
[http://dx.doi.org/10.1046/j.1365-2125.1998.00774.x] [PMID: 9764958]
[10]
Risk management plan in Japan. Available from: https://www.pmda.go.jp/files/000153352.pdf [cited 9th July 2021].
[11]
Kinoshita M, Yokote K, Arai H, et al. Japan atherosclerosis society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb 2018; 25(9): 846-984.
[http://dx.doi.org/10.5551/jat.GL2017] [PMID: 30135334]
[12]
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111-88.
[http://dx.doi.org/10.1093/eurheartj/ehz455] [PMID: 31504418]
[13]
Fruchart JC. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol 2017; 16(1): 124.
[http://dx.doi.org/10.1186/s12933-017-0602-y] [PMID: 28978316]
[14]
Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial. J Atheroscler Thromb 2018; 25(6): 521-38.
[http://dx.doi.org/10.5551/jat.44412] [PMID: 29628483]
[15]
Ida S, Kaneko R, Murata K. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis. Cardiovasc Diabetol 2019; 18(1): 38.
[http://dx.doi.org/10.1186/s12933-019-0845-x] [PMID: 30898163]
[16]
Risk management plan of pemafibrate in Japan. Available from: https://www.pmda.go.jp/RMP/www/270072/3c72b46b-7028-40c3-8d59-4599b5dfc7f4/270072_2183007F1025_004RMP.pdf [cited 20th May 2021].
[17]
Sørensen HT, Lash TL, Rothman KJ. Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. Hepatology 2006; 44(5): 1075-82.
[http://dx.doi.org/10.1002/hep.21404] [PMID: 17058242]
[18]
Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158(9): 915-20.
[http://dx.doi.org/10.1093/aje/kwg231] [PMID: 14585769]
[19]
Kaneko M, Motomura K, Mori H, et al. Gatekeeping function of primary care physicians under Japan’s free-access system: a prospective open cohort study involving 14 isolated islands. Fam Pract 2019; 36(4): 452-9.
[http://dx.doi.org/10.1093/fampra/cmy084] [PMID: 30202951]
[20]
Kubota K. Prescription-event monitoring in Japan (J-PEM). Drug Saf 2002; 25(6): 441-4.
[http://dx.doi.org/10.2165/00002018-200225060-00008] [PMID: 12071781]
[21]
National health insurance drug price listing in Japan (in Japanese). Available from: https://www.mhlw.go.jp/stf/shingi/2r9852000000uygm-att/2r98520 00000uymx.pdf [cited 20th May 2021].
[22]
Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991; 10(4): 577-81.
[http://dx.doi.org/10.1002/sim.4780100409] [PMID: 2057656]
[23]
Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356(9237): 1255-9.
[http://dx.doi.org/10.1016/S0140-6736(00)02799-9] [PMID: 11072960]
[24]
Yokotsuka M, Aoyama M, Kubota K. The use of a medical dictionary for regulatory activities terminology (MedDRA) in prescription-event monitoring in Japan (J-PEM). Int J Med Inform 2000; 57(2-3): 139-53.
[http://dx.doi.org/10.1016/S1386-5056(00)00062-9] [PMID: 10961570]
[25]
Mamdani M, Sykora K, Li P, et al. Reader’s guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 2005; 330(7497): 960-2.
[http://dx.doi.org/10.1136/bmj.330.7497.960] [PMID: 15845982]
[26]
Ooba N, Takahashi Y, Nagamura M, et al. Safety of elobixibat and lubiprostone in Japanese patients with chronic constipation: a retrospective cohort study. Expert Opin Drug Saf 2021; 20(12): 1553-8.
[http://dx.doi.org/10.1080/14740338.2021.1952980] [PMID: 34281471]
[27]
Revision of Good Post-Marketing Study Practice (GPSP). Available from: https://www.pmda.go.jp/files/000225335.pdf [cited 20th May 2021].
[28]
Takahashi N, Otake R, Hokugo J, et al. The survey of trends on Japanese post-marketing study after enforcement of revised Good Post-marketing Study Practice (GPSP). Jpn J Pharmacoepidemiol 2020; 25(1): 17-27.
[http://dx.doi.org/10.3820/jjpe.25.17]
[29]
Gremmels H, Joles JA. Fibrates in hypertension: where do we stand? J Hypertens 2018; 36(5): 1024-8.
[http://dx.doi.org/10.1097/HJH.0000000000001711] [PMID: 29578959]
[30]
Araki E, Yamashita S, Arai H, et al. Effects of Pemafibrate, a novel selective PPARa modulator, on lipid and glucose metabolism in patients with Type 2 Diabetes and hypertriglyceridemia: A randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2018; 41(3): 538-46.
[http://dx.doi.org/10.2337/dc17-1589] [PMID: 29298800]
[31]
Gilbert K, Nian H, Yu C, Luther JM, Brown NJ. Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension. J Hypertens 2013; 31(4): 820-9.
[http://dx.doi.org/10.1097/HJH.0b013e32835e8227] [PMID: 23385647]
[32]
Yamashita S, Masuda D, Matsuzawa Y. Clinical applications of a novel selective PPARα modulator, pemafibrate, in dyslipidemia and metabolic diseases. J Atheroscler Thromb 2019; 26(5): 389-402.
[http://dx.doi.org/10.5551/jat.48918] [PMID: 30930344]
[33]
Number of Pharmacies in Japan (in Japanese). Available from: https://www.mhlw.go.jp/toukei/saikin/hw/eisei_houkoku/18/dl/kekka5.pdf [cited 20th May 2021].

Rights & Permissions Print Cite
Article Metrics
28
1
© 2024 Bentham Science Publishers | Privacy Policy